Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Hypertension. 2021 May 24;78(1):230–240. doi: 10.1161/HYPERTENSIONAHA.121.17267

Figure 4. Rosiglitazone increases expression of PPARγ and GCM1 while simultaneously decreasing sFLT1 in sPE placenta.

Figure 4.

PPARγ protein expression significantly increased in sPE placenta after Rosiglitazone treatment (p=0.0051, n=4) (A/B). GCM1 mRNA significantly increased in the sPE placenta by Rosiglitazone treatment (p=0.0162, n=9). GCM1 mRNA expression significantly reduced in the sPE placenta after treatment with T0070907 (p=0.001, n=9) (C). sFLT1 mRNA was significantly reduced in the sPE placenta after Rosiglitazone treatment. No significant change in sFLT1 mRNA expression was observed after exposure to T0070907 (B).

(Relative mRNA/protein expressions were determined by normalization to respective housekeeping genes/protein. Relative expression values for individual tissue sets were normalized to DMSO (vehicle control, dotted line, set equal to 1) and subsequent statistical analysis was performed by student’s t-test to determine significant differences between groups, *p<0.05, **p<0.01, ns=p>0.05, NT= not treated, Rosi=Rosiglitazone, T007=T0070907, bar plots are reported as mean ± SEM).